Cargando…

Correction: Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection

Detalles Bibliográficos
Autores principales:	Duwal, Sulav, Schütte, Christof, von Kleist, Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525687/ http://dx.doi.org/10.1371/annotation/fb73d0f4-1cd8-481d-bddd-20439896102a

Ejemplares similares

Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection
por: Duwal, Sulav, et al.
Publicado: (2012)

Optimal Treatment Strategies in the Context of ‘Treatment for Prevention’ against HIV-1 in Resource-Poor Settings
por: Duwal, Sulav, et al.
Publicado: (2015)

In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis
por: Rath, Barbara A., et al.
Publicado: (2013)

Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis
por: Duwal, Sulav, et al.
Publicado: (2019)

Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes
por: Duwal, Sulav, et al.
Publicado: (2018)

The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis
por: Duwal, Sulav, et al.
Publicado: (2019)

Multiscale Systems‐Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV‐1
por: Duwal, S, et al.
Publicado: (2016)

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
por: Usach, Iris, et al.
Publicado: (2013)

Correction: Design and synthesis of tetrahydrophthalimide derivatives as inhibitors of HIV-1 reverse transcriptase
por: Penta, Ashok, et al.
Publicado: (2013)

Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV
por: von Kleist, Max, et al.
Publicado: (2020)

Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV
por: Iannuzzi, Sara, et al.
Publicado: (2021)

Deducing Mucosal Pharmacokinetics and Pharmacodynamics of the Anti-HIV Molecule Tenofovir from Measurements in Blood
por: Govil, Sachin, et al.
Publicado: (2019)

A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention
por: Jayachandran, Priya, et al.
Publicado: (2021)

HIV-1 Protease and Reverse Transcriptase Control the Architecture of Their Nucleocapsid Partner
Publicado: (2014)

Differential Binding of Tenofovir and Adefovir to Reverse Transcriptase of Hepatitis B Virus
por: van Hemert, Formijn J., et al.
Publicado: (2014)

Author correction to ‘Approved HIV reverse transcriptase inhibitors in the past decade’ [Acta Pharmaceutica Sinica B 12 (2022) 1567–1590]
por: Li, Guangdi, et al.
Publicado: (2023)

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2013)

Correction to: Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study
por: Riou, Julien, et al.
Publicado: (2021)

HIV-1 Polymerase Inhibition by Nucleoside Analogs: Cellular- and Kinetic Parameters of Efficacy, Susceptibility and Resistance Selection
por: von Kleist, Max, et al.
Publicado: (2012)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

Approved HIV reverse transcriptase inhibitors in the past decade
por: Li, Guangdi, et al.
Publicado: (2022)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
por: Mastan, SK, et al.
Publicado: (2009)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes
por: Zhang, Lanxin, et al.
Publicado: (2021)

Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir Resistance
por: Das, Kalyan, et al.
Publicado: (2009)

Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients
por: Micán, Rafael, et al.
Publicado: (2022)

Publisher Correction: Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin
por: Ruczyński, Jarosław, et al.
Publicado: (2019)

Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity
por: Ilina, Tatiana, et al.
Publicado: (2012)

Design and synthesis of tetrahydrophthalimide derivatives as inhibitors of HIV-1 reverse transcriptase
por: Penta, Ashok, et al.
Publicado: (2013)

Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase
por: Meleddu, Rita, et al.
Publicado: (2016)

HIV Resistance Prediction to Reverse Transcriptase Inhibitors: Focus on Open Data
por: Tarasova, Olga, et al.
Publicado: (2018)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
por: Famiglini, Valeria, et al.
Publicado: (2016)

Correction to: Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
por: Germovsek, Eva, et al.
Publicado: (2018)

Correction to: Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
por: Wenzler, Eric, et al.
Publicado: (2022)

Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women
por: Thurman, Andrea Ries, et al.
Publicado: (2018)

Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
por: Deeks, Emma D.
Publicado: (2019)

Reverse transcriptase activity in psoriatic lesions: effects of reverse transcriptase inhibitors on keratinocyte proliferation and differentiation
por: Molès, Jean-Pierre, et al.
Publicado: (2009)

Correction: The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients
por: Rampazzo, Enrica, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s7ad7oj8f4afjfg8t7k807ccvo